Loading...

PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405203 100 µg 45€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405204 500 µg 156€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  2. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  3. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  4. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  5. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  6. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  7. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  8. Goel RR, et al. 2022. Cell. 185:1875. PubMed
  9. Campisi L, et al. 2022. Nature. 606:945. PubMed
  10. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  11. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
  12. Cao Y, et al. 2023. Nature. 614:521. PubMed
  13. Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed
  14. Mekkaoui L, et al. 2023. Mol Ther Methods Clin Dev. 28:116. PubMed
  15. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  16. Hernandez SPA, et al. 2023. Front Immunol. 13:1035344. PubMed
  17. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  18. Knyphausen P, et al. 2023. Nat Commun. 14:768. PubMed
  19. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  20. Feng J, et al. 2022. Immunity. 55:405. PubMed
  21. Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed
  22. Melzi E, et al. 2022. Immunity. 55:2168. PubMed
  23. Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed
  24. Ke F, et al. 2023. Elife. 12:. PubMed
  25. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  26. Silva RP, et al. 2023. Elife. 12:. PubMed
  27. Nozuma S, et al. 2023. JCI Insight. 8:. PubMed
  28. García-Vega M, et al. 2023. iScience. 26:106562. PubMed
  29. Liu Y, et al. 2023. Nat Commun. 14:2179. PubMed
  30. Fathi M, et al. 2023. iScience. 26:106482. PubMed
  31. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  32. Lv X, et al. 2023. Acta Pharm Sin B. 13:1631. PubMed
  33. Li X, et al. 2023. Nat Commun. 14:2929. PubMed
  34. Tundidor I, et al. 2023. Nat Commun. 14:3130. PubMed
  35. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  36. Golubovskaya V, et al. 2023. Cancers (Basel). 15:. PubMed
  37. Feng, D., Guo, J., et al. 2025. Microbiol Spectr. 13(10),e0136225. PubMed
  38. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  39. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  40. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  41. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  42. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  43. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  44. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  45. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  46. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  47. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  48. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  49. Gniffke EP, et al. 2020. medRxiv. . PubMed
  50. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  51. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  52. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  53. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  54. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  55. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  56. Biswas S, et al. 2021. Nature. 591:464. PubMed
  57. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  58. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  59. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  60. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  61. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  62. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  63. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  64. Im S, et al. 2016. Nature. 537:417-421. PubMed
  65. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  66. Cao Y, et al. 2022. Nature. :. PubMed
  67. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  68. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  69. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  70. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  71. Schanda N, et al. 2021. Cells. 10:. PubMed
  72. Köchl R, et al. 2020. Elife. 9:00. PubMed
  73. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  74. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  75. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  76. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  77. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  78. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  79. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  80. Cao Y, et al. 2022. Nature. 602:657. PubMed
  81. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  82. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  83. Weiß S, et al. 2020. medRxiv. . PubMed
  84. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  85. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  86. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  87. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  88. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  89. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  90. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  91. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  92. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  93. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  94. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  95. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  96. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  97. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  98. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  99. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  100. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  101. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  102. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  103. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  104. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  105. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  106. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  107. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  108. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  109. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  110. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  111. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  112. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  113. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  114. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  115. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  116. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  117. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  118. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  119. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  120. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  121. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  122. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  123. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  124. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  125. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  126. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  127. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  128. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  129. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  130. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  131. Dan JM, et al. 2021. Science. :371. PubMed
  132. He X, et al. 2014. J Immunol. 193:1314. PubMed
  133. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  134. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  135. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  136. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  137. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  138. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  139. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  140. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  141. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  142. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  143. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  144. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  145. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  146. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  147. Wells DK, et al. 2020. Cell. 183:818. PubMed
  148. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  149. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  150. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  151. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  152. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  153. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  154. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  155. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  156. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  157. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  158. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  159. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  160. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  161. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  162. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  163. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06/17/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account